OverviewSuggest Edit

Biogen is a biopharmaceutical company that discovers, develops and delivers innovative therapies for people living with serious neurological and neurodegenerative diseases. It is primarily focused on developing medicines to treat multiple sclerosis, spinal muscular atrophy, Alzheimer’s disease, Parkinson’s disease, and amyotrophic lateral sclerosis. The company also manufactures and commercializes biosimilars of advanced biologics.
TypePublic
Founded1978
HQCambridge, US
Websitebiogen.com
Employee Ratings3.4
Culture scoreB

Latest Updates

Employees (est.) (Dec 2019)7,400(-5%)
Job Openings732
Revenue (FY, 2019)$14.4 B(+7%)
Share Price (Jun 2020)$299.6

Key People/Management at Biogen

Michel Vounatsos

Michel Vounatsos

Chief Executive Officer and Director
Stelios Papadopoulos

Stelios Papadopoulos

Chairman of the Board
Susan Alexander

Susan Alexander

Executive Vice President, Chief Legal Officer and Secretary
Jeffrey Capello

Jeffrey Capello

Executive Vice President, Chief Financial Officer
Alphonse Galdes

Alphonse Galdes

Executive Vice President, Pharmaceutical Operations and Technology
Ginger Gregory

Ginger Gregory

Executive Vice President, Chief Human Resource Officer
Show more

Biogen Office Locations

Biogen has offices in Cambridge, Morrisville, Waltham, Washington and in 35 other locations
Cambridge, US (HQ)
225 Binney St
Morrisville, US
5000 Davis Dr
Waltham, US
203 Crescent St #303
Washington, US
601 Pennsylvania Ave NW #720
Weston, US
133 Boston Post Rd
Vicente López, AR
7th Floor, Av. del Libertador 350
Show all (39)

Biogen Financials and Metrics

Biogen Revenue

Embed Graph
View revenue for all periods
Biogen's revenue was reported to be $14.38 b in FY, 2019 which is a 6.9% increase from the previous period.
USD

Revenue (Q1, 2020)

3.5b

Gross profit (Q1, 2020)

3.1b

Gross profit margin (Q1, 2020), %

87.1%

Net income (Q1, 2020)

1.4b

EBIT (Q1, 2020)

1.8b

Market capitalization (4-Jun-2020)

48.9b

Closing stock price (4-Jun-2020)

299.6

Cash (31-Mar-2020)

2.6b

EV

52.7b
Biogen's current market capitalization is $48.9 b.
Annual
USDFY, 2017FY, 2018FY, 2019

Revenue

12.3b13.5b14.4b

Revenue growth, %

10%7%

Cost of goods sold

1.6b1.8b2.0b

Gross profit

10.6b11.6b12.4b
Quarterly
USDQ1, 2017Q2, 2017Q3, 2017Q1, 2018Q2, 2018Q3, 2018Q1, 2019Q2, 2019Q3, 2019Q1, 2020

Revenue

2.8b3.1b3.1b3.1b3.4b3.4b3.5b3.6b3.6b3.5b

Cost of goods sold

384.6m366.2m370.0m446.0m421.0m460.8m602.0m476.3m430.0m454.3m

Gross profit

2.4b2.7b2.7b2.7b2.9b3.0b2.9b3.1b3.2b3.1b

Gross profit Margin, %

86%88%88%86%87%87%83%87%88%87%
Annual
USDFY, 2017FY, 2018FY, 2019

Cash

1.6b1.2b2.9b

Accounts Receivable

1.8b2.0b1.9b

Inventories

902.7m929.9m804.2m

Current Assets

7.9b7.6b8.4b
Quarterly
USDQ1, 2017Q2, 2017Q3, 2017Q1, 2018Q2, 2018Q3, 2018Q1, 2019Q2, 2019Q3, 2019Q1, 2020

Cash

924.0m1.2b1.5b4.1b1.3b2.4b2.2b1.7b2.3b2.6b

Accounts Receivable

1.5b1.6b1.6b1.9b2.0b2.0b2.1b2.0b1.9b2.1b

Inventories

921.6m936.5m1.0b890.8m931.7m916.6m770.2m776.7m751.8m858.8m

Current Assets

6.9b7.1b7.6b10.2b7.4b8.7b8.9b7.9b8.4b8.0b
Annual
USDFY, 2017FY, 2018FY, 2019

Net Income

2.7b4.5b5.9b

Depreciation and Amortization

1.1b1.0b680.6m

Inventories

(94.5m)(52.1m)(19.2m)

Cash From Operating Activities

4.6b6.2b7.1b
Quarterly
USDQ1, 2017Q2, 2017Q3, 2017Q1, 2018Q2, 2018Q3, 2018Q1, 2019Q2, 2019Q3, 2019Q1, 2020

Net Income

747.5m1.6b2.8b1.2b2.1b3.5b1.4b2.9b4.4b1.4b

Depreciation and Amortization

512.0m814.6m992.0m168.9m340.4m686.9m121.1m238.1m567.6m119.9m

Inventories

(46.2m)(85.3m)(170.3m)(2.6m)(40.1m)(31.9m)(129.0m)(108.7m)(47.3m)(62.2m)

Cash From Operating Activities

235.2m1.4b3.0b1.5b2.6b4.3b1.5b3.4b5.1b1.5b
USDY, 2020

EV/EBIT

28.9 x

EV/CFO

35.9 x

Financial Leverage

2.1 x
Show all financial metrics

Biogen Operating Metrics

FY, 2016FY, 2017FY, 2018Q1, 2019Q2, 2019Q3, 2019FY, 2019

Phase I Trials Products

4 4 7 6 8 9 9

Phase I/II Trials Products

1

Phase II Trials Products

10 12 13 13 12 12 11

Phase III Trials Products

2 3 4 3 5 5 6
Show all operating metrics

Biogen Acquisitions / Subsidiaries

Company NameDateDeal Size
Nightstar TherapeuticsMarch 04, 2019$800 m
AliveGenJuly 25, 2018$27.50 m
Karyopharm TherapeuticsJanuary 25, 2018$10 m
Remedy PharmaceuticalsMay 18, 2017$120 m
Convergence PharmaceuticalsFebruary 14, 2014$675 m
StromedixFebruary 14, 2014$75 m
TysabriFebruary 28, 2013
Syntonix PharmaceuticalsJanuary 04, 2007$120 m
FumapharmMay 31, 2006
Conforma TherapeuticsMay 03, 2006$150 m
Show more

Biogen Revenue Breakdown

Embed Graph

Biogen revenue breakdown by business segment: 15.9% from Anti-CD20 Therapeutic Programs, 79.1% from Product Revenues and 4.9% from Other

Biogen Online and Social Media Presence

Embed Graph

Biogen Company Culture

  • Overall Culture

    B

    72/100

  • CEO Rating

    C-

    65/100

  • Compensation

    A+

    84/100

  • Diversity

    A

    81/100

Learn more on Comparably

Biogen News and Updates

Biogen Presents Positive Phase 2 Cutaneous Lupus Erythematosus (CLE) Data at European E-Congress of Rheumatology (EULAR) 2020

CAMBRIDGE, Mass., June 04, 2020 (GLOBE NEWSWIRE) -- Today, Biogen Inc. (Nasdaq: BIIB) shared positive data from the 16-week cutaneous lupus erythematosus (CLE) portion of the Phase 2 LILAC study. The study evaluated the efficacy and safety of BIIB059, a fully humanized IgG1 monoclonal antibody (mA…

Biogen and MIT Launch New Virtual Learning Lab for High School Students Historically Underrepresented in Science

CAMBRIDGE, Mass., May 28, 2020 (GLOBE NEWSWIRE) -- Biogen Inc. (Nasdaq: BIIB) is bringing its well-recognized Community Lab science learning program together with the Lemelson-MIT Program (LMIT) at the Massachusetts Institute of Technology to launch the new online Biogen-MIT Biotech in Action: Vir…

NYT: Biogen event led to 'superspreading' of COVID-19 among employees and their contacts

Shares of Biogen Inc. were down 0.3% in premarket trading on Monday after The New York Times reported on Sunday that a company event in late February led to "superspreading" of COVID-19 among its employees. Even after reports of positive tests among employees who attended the meeting came in, at le…

Thinking about trading options or stock in Biogen, Clorox, Centene, Netflix, or Walmart?

NEW YORK, March 16, 2020 /PRNewswire/ -- InvestorsObserver issues critical PriceWatch Alerts for BIIB, CLX, CNC, NFLX, and WMT. Click a link below then choose between in-depth options trade idea report or a stock score report. Options Report – Ideal trade ideas on up to seven different...

Vir's stock gains 15% as it announces COVID-19 collaboration with Biogen

Shares of Vir Biotechnology Inc. gained 15% in premarket trading on Thursday after it said it intends to partner with Biogen Inc. to help develop and manufacture its monoclonal antibodies as a potential treatment of COVID-19. Biogen will handle clinical manufacturing of Vir's antibodies, the compa…

Biogen orders all workers to work from home after employees at management meeting test positive for coronavirus

Biogen Inc. has ordered all of its workers to work from home until further notice, as part of a sweeping round of measures implemented after employees who attended a Boston management meeting tested positive for the coronavirus that causes COVID-19. Biogen had about 7,400 employees worldwide as of …
Show more

Biogen Blogs

Biogen to Report First Quarter 2020 Financial Results April 22, 2020

Cambridge, Mass.— Biogen Inc. (Nasdaq:BIIB) today announced it will report first quarter 2020 financial results Wednesday, April 22, 2020, before the financial markets open. Following the release of the financials, the Company will host a live webcast with Biogen management at 8:00 a.m. ET.

Biogen Announces First Patient Treated With Higher Dose of SPINRAZA® (nusinersen) in Phase 2/3 DEVOTE Study

DEVOTE will evaluate the safety and potential for even greater efficacy of a higher dose of SPINRAZA in the treatment of spinal muscular atrophy (SMA) Well-established safety profile and proven efficacy of SPINRAZA in a broad range of patients supports exploration of the higher dose Biogen

Biogen to Webcast Encore Aducanumab Presentation From Virtual AAT-AD/PD Meeting on April 2, 2020

Cambridge, Mass. – March 30, 2020 – Biogen (Nasdaq: BIIB) today announced it will host a webcast of its encore presentation related to its Alzheimer’s disease investigational therapy, aducanumab, at the upcoming virtual AAT-AD/PDTM focus meeting. The data in this presentation were previously

Biogen Statement: Business Update Regarding COVID-19

The current COVID-19 pandemic has presented a substantial public health and economic challenge around the world. As governments, businesses and other organizations take unprecedented measures to help mitigate the spread of the outbreak, we want to reinforce our deep commitment to our employees, our

Biogen Foundation Commits $10 Million to Support COVID-19 Relief Efforts in the U.S. and Around the World

Most of the funds will be directed to support the global response and the immediate needs of communities hardest hit by COVID-19 CAMBRIDGE, Mass., March 16, 2020 (GLOBE NEWSWIRE) -- Biogen Inc . (Nasdaq: BIIB) today announced that the Biogen Foundation has committed $10 million to support global

Biogen and Sangamo Announce Global Collaboration to Develop Gene Regulation Therapies for Alzheimer’s, Parkinson’s, Neuromuscular, and Other Neurological Diseases

Broad collaboration for gene regulation therapies in neurology, initially focused on development of ST-501 for tauopathies including Alzheimer’s disease, ST-502 for synucleinopathies including Parkinson’s disease, and a neuromuscular target, with exclusive rights for nine additional undisclosed
Show more

Biogen Frequently Asked Questions

  • When was Biogen founded?

    Biogen was founded in 1978.

  • Who are Biogen key executives?

    Biogen's key executives are Michel Vounatsos, Stelios Papadopoulos and Susan Alexander.

  • How many employees does Biogen have?

    Biogen has 7,400 employees.

  • What is Biogen revenue?

    Latest Biogen annual revenue is $14.4 b.

  • What is Biogen revenue per employee?

    Latest Biogen revenue per employee is $1.9 m.

  • Who are Biogen competitors?

    Competitors of Biogen include Bayer, Amgen and Gilead Sciences.

  • Where is Biogen headquarters?

    Biogen headquarters is located at 225 Binney St, Cambridge.

  • Where are Biogen offices?

    Biogen has offices in Cambridge, Morrisville, Waltham, Washington and in 35 other locations.

  • How many offices does Biogen have?

    Biogen has 39 offices.